Export 13 results:
Autore [ Titolo(Desc)] Tipo Anno
Filtri: Autore è Voltan, Rebecca  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Secchiero P, Rimondi E, di Iasio MGrazia, Voltan R, Gonelli A, Zauli G. Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages. J Cell Physiol 2012;227(5):1829-37.
Bosco R, Rabusin M, Voltan R, Celeghini C, Corallini F, Capitani S, Secchiero P. Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells. Invest New Drugs 2012;30(1):417-22.
Biffi S, Voltan R, Rampazzo E, Prodi L, Zauli G, Secchiero P. Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery. Expert Opin Drug Deliv 2015;:1-13.
D
Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GMatteo, Cuneo A, Secchiero P. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 2011;17(4):762-70.
Trapella C, Voltan R, Melloni E, Tisato V, Celeghini C, Bianco S, Fantinati A, Salvadori S, Guerrini R, Secchiero P, Zauli G. Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. J Med Chem 2015;
E
Tisato V, Zauli G, Voltan R, Gianesini S, di Iasio MGrazia, Volpi I, Fiorentini G, Zamboni P, Secchiero P. Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype. PLoS One 2012;7(6):e39543.
H
Campioni D, Voltan R, Tisato V, Zauli G. Heterogeneity of mesenchymal stromal cells in lymphoproliferative disorders. Front Biosci (Landmark Ed) 2014;19:139-51.
I
Voltan R, Zauli G, Rizzo P, Fucili A, Pannella M, Marci R, Tisato V, Ferrari R, Secchiero P. In vitro endothelial cell proliferation assay reveals distinct levels of proangiogenic cytokines characterizing sera of healthy subjects and of patients with heart failure. Mediators Inflamm 2014;2014:257081.
M
Secchiero P, Melloni E, Voltan R, Norcio A, Celeghini C, Zauli G. MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. Br J Haematol 2012;157(4):510-4.
Zauli G, Voltan R, di Iasio MGrazia, Bosco R, Melloni E, Sana MElena, Secchiero P. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011;17(9):2712-24.
N
di Iasio MGrazia, Addobbati R, Radillo O, Voltan R. Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples. Invest New Drugs 2012;30(4):1761-5.
P
Athanasakis E, Melloni E, Rigolin GMatteo, Agnoletto C, Voltan R, Vozzi D, Piscianz E, Segat L, dal Monego S, Cuneo A, Secchiero P, Zauli G. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. Oncotarget 2014;5(24):12635-45.

Amministrazione Trasparente